Technology-Assisted Cholesterol Trial in Consumers (TACTiC) - TACTiC

Study identifier:D356PL00015

ClinicalTrials.gov identifier:NCT04964544

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase III, 6-Month Self-selection and Actual Use Study for Rx-to-OTC Switch of rosuvastatin 5 mg once-daily in combination with a Web App

Medical condition

High Cholesterol

Phase

Phase 3

Healthy volunteers

No

Study drug

5 mg rosuvastatin calcium with a Web App (combination product)

Sex

All

Actual Enrollment

1196

Study type

Interventional

Age

20 Years - 75 Years

Date

Study Start Date: 08 Jul 2021
Primary Completion Date: 01 Mar 2023
Study Completion Date: 01 Mar 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

Concentrics Research LLC, Concentrics Research - STATKING JV, Idea Evolver, Cleveland Clinic

Inclusion and exclusion criteria